Davide Bolignano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8632585/publications.pdf

Version: 2024-02-01

172 papers 6,340 citations

39 h-index 79698 73 g-index

179 all docs

179 docs citations

179 times ranked 8355 citing authors

#	Article	IF	CITATIONS
1	Circulating Omentin-1 levels and altered iron balance in chronic haemodialysis patients. CKJ: Clinical Kidney Journal, 2022, 15, 303-310.	2.9	4
2	Autosomic dominant polycystic kidney disease and metformin: Old knowledge and new insights on retarding progression of chronic kidney disease. Medicinal Research Reviews, 2022, 42, 629-640.	10.5	7
3	Translational research in nephrology: prognosis. CKJ: Clinical Kidney Journal, 2022, 15, 205-212.	2.9	O
4	Assessment of hypertension in kidney transplantation by ambulatory blood pressure monitoring: a systematic review and meta-analysis. CKJ: Clinical Kidney Journal, 2022, 15, 31-42.	2.9	14
5	Hyperkalemia excursions and risk of mortality and hospitalizations in hemodialysis patients: results from DOPPS-Italy. Journal of Nephrology, 2022, 35, 707-709.	2.0	1
6	Marinobufagenin, left ventricular geometry and cardiac dysfunction in end-stage kidney disease patients. International Urology and Nephrology, 2022, 54, 2581-2589.	1.4	7
7	MO732: Circulating Omentin-1 and Subclinical Atherosclerosis in Chronic H a emodialysis Patients: A Pilot Study. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
8	MO354: Selenium-Binding Protein 1 (Sepp1) as an Early Sensitive Biomarker of Acute Kidney Injury in Patients Undergoing Cardiopulmonary Bypass. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
9	Role of Vitamin K in Chronic Kidney Disease: A Focus on Bone and Cardiovascular Health. International Journal of Molecular Sciences, 2022, 23, 5282.	4.1	10
10	Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy. Medicina (Lithuania), 2022, 58, 890.	2.0	1
11	Cathepsin-K is a potential cardiovascular risk biomarker in prevalent hemodialysis patients. International Urology and Nephrology, 2021, 53, 171-175.	1.4	5
12	Increased circulating Cathepsin-K levels reflect PTH control in chronic hemodialysis patients. Journal of Nephrology, 2021, 34, 451-458.	2.0	2
13	Serum gamma-glutamyltransferase, oxidized LDL and mortality in the elderly. Aging Clinical and Experimental Research, 2021, 33, 1393-1397.	2.9	10
14	Antecedent ACE-inhibition, inflammatory response, and cardiac surgery associated acute kidney injury. Reviews in Cardiovascular Medicine, 2021, 22, 207.	1.4	8
15	OCT angiography metrics predict intradialytic hypotension episodes in chronic hemodialysis patients: a pilot, prospective study. Scientific Reports, 2021, 11, 7202.	3.3	10
16	Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage. Nephrology Dialysis Transplantation, 2021, 36, 1326-1346.	0.7	18
17	MO462TIME-TRAJECTORIES OF RENAL FUNCTION AND OUTCOMES IN ELDERLY INDIVIDUALS WITH CKD OF VARIOUS ETIOLOGY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
18	MO791HIGH-SENSITIVITY CARDIAC TROPONIN I CORRELATES WITH THE CARDIAC DYSFUNCTION AND WITH THE SEVERITY OF ANEMIA IN DIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0

#	Article	IF	Citations
19	MO911ALTERED CIRCULATING OMENTIN-1 LEVELS REFLECT IRON DEFICIENCY IN CHRONIC HEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	O
20	MO291RITUXIMAB IS EFFECTIVE AND SAFE IN ADULTS WITH STEROID-DEPENDENT NEPHROTIC SYNDROME: A LONG-TERM, SINGLE-CENTER EXPERIENCE. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
21	Nephrosclerosis impacts time trajectory of renal function and outcomes in elderly individuals with chronic kidney disease. Journal of Investigative Medicine, 2021, 69, jim-2021-001854.	1.6	2
22	Smoking habit as a risk amplifier in chronic kidney disease patients. Scientific Reports, 2021, 11, 14778.	3.3	10
23	Retarding Progression of Chronic Kidney Disease in Autosomal Dominant Polycystic Kidney Disease with Metformin and Other Therapies: An Update of New Insights. International Journal of General Medicine, 2021, Volume 14, 5993-6000.	1.8	2
24	Hypoxia-Inducible Factor Stabilizers in End Stage Kidney Disease: "Can the Promise Be Kept?― International Journal of Molecular Sciences, 2021, 22, 12590.	4.1	7
25	Renal denervation for resistant hypertension. The Cochrane Library, 2021, 2021, CD011499.	2.8	9
26	Management of obesity in kidney transplant candidates and recipients: A clinical practice guideline by the DESCARTES Working Group of ERA. Nephrology Dialysis Transplantation, 2021, 37, i1-i15.	0.7	25
27	Altered circulating marinobufagenin levels and recurrent intradialytic hypotensive episodes in chronic hemodialysis patients: a pilot, prospective study. Reviews in Cardiovascular Medicine, 2021, 22, 1577.	1.4	7
28	Comparative effectiveness of different antihypertensive agents in kidney transplantation: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2020, 35, 878-887.	0.7	32
29	COVID‶9 clinical manifestations and treatment strategies among solidâ€organ recipients: A systematic review of cases. Transplant Infectious Disease, 2020, 22, e13427.	1.7	23
30	Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. The Cochrane Library, 2020, 2020, CD007004.	2.8	41
31	COVID-19 and renal disease in elderly patients. Geriatric Care, 2020, 6, .	0.2	6
32	Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases. Pharmacological Research, 2020, 159, 105019.	7.1	11
33	Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) Predicts Renal Function Decline in Patients With Glomerular Diseases. Frontiers in Cell and Developmental Biology, 2020, 8, 336.	3.7	8
34	RAS inhibition modulates kynurenine levels in a CKD population with and without type 2 diabetes mellitus. International Urology and Nephrology, 2020, 52, 1125-1133.	1.4	14
35	Utility of Blood Flow/Resistance Index Ratio (Qx) as a Marker of Stenosis and Future Thrombotic Events in Native Arteriovenous Fistulas. Frontiers in Surgery, 2020, 7, 604347.	1.4	3
36	Delirium accompanies kidney dysfunction in hospitalized elderly patients. Journal of Gerontology and Geriatrics, 2020, 68, 24-30.	0.5	3

#	Article	IF	Citations
37	Clinical practice guideline on peri- and postoperative care of arteriovenous fistulas and grafts for haemodialysis in adults. Nephrology Dialysis Transplantation, 2019, 34, ii1-ii42.	0.7	94
38	Unraveling Cardiovascular Risk in Renal Patients: A New Take on Old Tale. Frontiers in Cell and Developmental Biology, 2019, 7, 314.	3.7	62
39	Sympathetic neural overdrive in congestive heart failure and its correlates. Journal of Hypertension, 2019, 37, 1746-1756.	0.5	34
40	Pulmonary Hypertension Predicts Adverse Outcomes in Renal Patients: A Systematic Review and Metaâ€Analysis. Therapeutic Apheresis and Dialysis, 2019, 23, 369-384.	0.9	12
41	Oxidative Stress and Kidney Function: A Brief Update. Current Pharmaceutical Design, 2019, 24, 4794-4799.	1.9	57
42	Baroreflex stimulation for treating resistant hypertension: ready for the prime-time?. Reviews in Cardiovascular Medicine, 2019, 19, 89-95.	1.4	3
43	Renal nerve ablation for resistant hypertension: facts, fictions and future directions. Reviews in Cardiovascular Medicine, 2019, 20, 9.	1.4	3
44	Prevalence and burden of chronic kidney disease among the general population and high-risk groups in Africa: a systematic review. BMJ Open, 2018, 8, e015069.	1.9	99
45	Effect of renin–angiotensin–aldosterone system blockade in adults with diabetes mellitus and advanced chronic kidney disease not on dialysis: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2018, 33, 12-22.	0.7	39
46	Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials. Pharmacological Research, 2018, 129, 274-294.	7.1	47
47	Short-term vascular hemodynamic responses to isometric exercise in young adults and in the elderly. Clinical Interventions in Aging, 2018, Volume 13, 509-514.	2.9	10
48	Biotic Supplements for Renal Patients: A Systematic Review and Meta-Analysis. Nutrients, 2018, 10, 1224.	4.1	29
49	Kidney function and cognitive decline in frail elderly: two faces of the same coin?. International Urology and Nephrology, 2018, 50, 1505-1510.	1.4	32
50	Sympathetic Nerve Traffic Activation in Essential Hypertension and Its Correlates. Hypertension, 2018, 72, 483-491.	2.7	79
51	Endothelial Progenitor Cells at the Interface of Chronic Kidney Disease: From Biology to Therapeutic Advancement. Current Medicinal Chemistry, 2018, 25, 4545-4551.	2.4	6
52	Pulmonary hypertension: a neglected risk condition in renal patients?. Reviews in Cardiovascular Medicine, 2018, 19, 117-121.	1.4	9
53	Renal biopsy in patients with diabetes: a pooled meta-analysis of 48 studies. Nephrology Dialysis Transplantation, 2017, 32, gfw070.	0.7	103
54	Renal denervation for resistant hypertension. The Cochrane Library, 2017, 2017, CD011499.	2.8	29

#	Article	IF	CITATIONS
55	Cochrane corner: renal denervation for resistant hypertension—a broken promise?. Heart, 2017, 103, 1753-1755.	2.9	0
56	Effects of Vitamin E-Coated versus Conventional Membranes in Chronic Hemodialysis Patients: A Systematic Review and Meta-Analysis. Blood Purification, 2017, 43, 101-122.	1.8	44
57	Exercise in Patients on Dialysis: A Multicenter, Randomized Clinical Trial. Journal of the American Society of Nephrology: JASN, 2017, 28, 1259-1268.	6.1	272
58	Non-proteinuric rather than proteinuric renal diseases are the leading cause of end-stage kidney disease. Nephrology Dialysis Transplantation, 2017, 32, ii194-ii199.	0.7	30
59	Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2017, 91, 24-33.	5.2	230
60	Renal safety of catheter-based renal denervation: systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2017, 32, 1440-1447.	0.7	47
61	Gender at the Interface of Renal Aging. , 2017, , 621-638.		0
62	Xanthine Oxidase Inhibitors for Improving Renal Function in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2017, 18, 2283.	4.1	41
63	Antioxidant agents for delaying diabetic kidney disease progression: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0178699.	2.5	87
64	SP628BENEFITS OF VITAMIN E-COATED VERSUS CONVENTIONAL MEMBRANES IN CHRONICHAEMODIALYSIS PATIENTS: A SYSTEMATIC REVIEW & mp; META-ANALYSIS. Nephrology Dialysis Transplantation, 2016, 31, i304-i305.	0.7	0
65	Good-quality research in rare diseases: trials and tribulations. Pediatric Nephrology, 2016, 31, 2017-2023.	1.7	10
66	Timing of start of dialysis in diabetes mellitus patients: a systematic literature review. Nephrology Dialysis Transplantation, 2016, 31, gfv431.	0.7	16
67	Effect of pentoxifylline on renal outcomes in chronic kidney disease patients: A systematic review and meta-analysis. Pharmacological Research, 2016, 107, 315-332.	7.1	30
68	Priority topics for European multidisciplinary guidelines on the management of chronic kidney disease in older adults. International Urology and Nephrology, 2016, 48, 859-869.	1.4	12
69	Serum phosphate modifies the vascular response to vitamin D receptor activation in chronic kidney disease (CKD) patients. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 581-589.	2.6	11
70	Renal Biopsy in 2015 - From Epidemiology to Evidence-Based Indications. American Journal of Nephrology, 2016, 43, 1-19.	3.1	106
71	The Dark Side of Blocking RAS in Diabetic Patients with Incipient or Manifested Nephropathy. Experimental and Clinical Endocrinology and Diabetes, 2016, 124, 350-360.	1.2	11
72	High versus low dialysate sodium concentration in chronic haemodialysis patients: a systematic review of 23 studies. Nephrology Dialysis Transplantation, 2016, 31, 548-563.	0.7	42

#	Article	IF	CITATIONS
73	Kidney and Neoplastic Disease: Overview with a Particular Interest to Interpretation of Cancer Biomarkers. , 2016, , 249-268.		1
74	Overview of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Biomarker in Nephrology. , 2016, , 205-227.		0
7 5	Pulmonary Pressure as a Novel Prognostic Biomarker in Renal Patients. , 2016, , 1121-1141.		O
76	Interventions for preventing the progression of autosomal dominant polycystic kidney disease. The Cochrane Library, 2015, , CD010294.	2.8	26
77	Preferred Haemodialysis Vascular Access for Diabetic Chronic Kidney Disease Patients: A Systematic Literature Review. Journal of Vascular Access, 2015, 16, 259-264.	0.9	16
78	FP700DIALYSATE SODIUM PRESCRIPTION IN CHRONIC HEMODIALYSIS PATIENTS: A SYSTEMATIC REVIEW OF 21 STUDIES. Nephrology Dialysis Transplantation, 2015, 30, iii309-iii310.	0.7	0
79	FP376THE BURDEN OF CKD IN HIGH RISK CONDITIONS IN THE AFRICAN CONTINENT: A SYSTEMATIC REVIEW. Nephrology Dialysis Transplantation, 2015, 30, iii194-ii194.	0.7	O
80	SP358PULMONARY HYPERTENSION PREDICTS ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH NON-ADVANCED CKD. Nephrology Dialysis Transplantation, 2015, 30, iii497-iii497.	0.7	0
81	SP383THE CKD EPIDEMIC IN THE AFRICAN CONTINENT: A SYSTEMATIC REVIEW. Nephrology Dialysis Transplantation, 2015, 30, iii505-iii506.	0.7	O
82	Why creating standardized core outcome sets for chronic kidney disease will improve clinical practice. Nephrology Dialysis Transplantation, 2015, 32, gfv365.	0.7	18
83	Physical excercise programs in CKD: lights, shades and perspectives: a position paper of the "Physical Exercise in CKD Study Group―of the Italian Society of Nephrology. Journal of Nephrology, 2015, 28, 143-150.	2.0	40
84	Pulmonary Hypertension in CKD: A New Problem Child. , 2015, , 153-162.		0
85	Dialysis modality choice in diabetic patients with end-stage kidney disease: a systematic review of the available evidence. Nephrology Dialysis Transplantation, 2015, 30, 310-320.	0.7	47
86	High estimated pulmonary artery systolic pressure predicts adverse cardiovascular outcomes in stage 2–4 chronic kidney disease. Kidney International, 2015, 88, 130-136.	5.2	31
87	Validity of Vascular Calcification as a Screening Tool and as a Surrogate End Point in Clinical Research. Hypertension, 2015, 66, 3-9.	2.7	23
88	Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR < 45 mL/min). Nephrology Dialysis Transplantation, 2015, 30, ii1-ii142.	0.7	113
89	Pentoxifylline for Anemia in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0134104.	2.5	15
90	Overview of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Biomarker in Nephrology. , 2015, , 1-24.		0

#	Article	IF	Citations
91	Pulmonary Pressure as a Novel Prognostic Biomarker in Renal Patients., 2015, , 1-21.		O
92	Kidney and Neoplastic Disease: Overview with a Particular Interest to Interpretation of Cancer Biomarkers., 2015,, 1-20.		0
93	Dietary Restriction and Exercise for Diabetic Patients with Chronic Kidney Disease: A Systematic Review. PLoS ONE, 2014, 9, e113667.	2.5	30
94	Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties. Nephrology Dialysis Transplantation, 2014, 29, 1284-1300.	0.7	69
95	Paricalcitol and Endothelial Function in Chronic Kidney Disease Trial. Hypertension, 2014, 64, 1005-1011.	2.7	106
96	Tumour Markers and Kidney Function: A Systematic Review. BioMed Research International, 2014, 2014, 1-9.	1.9	41
97	Providing guidance in the dark: rare renal diseases and the challenge to improve the quality of evidence. Nephrology Dialysis Transplantation, 2014, 29, 1628-1632.	0.7	11
98	European Renal Best Practice (ERBP) Guideline development methodology: towards the best possible guidelines. Nephrology Dialysis Transplantation, 2014, 29, 731-738.	0.7	27
99	Emerging markers of cachexia predict survival in cancer patients. BMC Cancer, 2014, 14, 828.	2.6	44
100	Fitness for Entering a Simple Exercise Program and Mortality: A Study Corollary to the Exercise Introduction to Enhance Performance in Dialysis (Excite) Trial. Kidney and Blood Pressure Research, 2014, 39, 197-204.	2.0	17
101	Physical Performance and Clinical Outcomes in Dialysis Patients: A Secondary Analysis of the Excite Trial. Kidney and Blood Pressure Research, 2014, 39, 205-211.	2.0	72
102	Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1447-56.	2.3	107
103	Relaxin: New Pathophysiological Aspects and Pharmacological Perspectives for an Old Protein. Medicinal Research Reviews, 2014, 34, 77-105.	10.5	46
104	Biomarkers of cardio-renal damage in chronic kidney disease: one size cannot fit all. Critical Care, 2014, 18, 134.	5.8	7
105	The aging kidney revisited: A systematic review. Ageing Research Reviews, 2014, 14, 65-80.	10.9	191
106	Erythropoiesis-Stimulating Agents (ESA) for Preventing the Progression of Chronic Kidney Disease: A Meta-Analysis of 19 Studies. American Journal of Nephrology, 2014, 40, 263-279.	3.1	27
107	Aldosterone antagonists for preventing the progression of chronic kidney disease. The Cochrane Library, 2014, , CD007004.	2.8	102
108	Corrigendum to "Glitazones in chronic kidney disease: Potential and concerns―[Nutr Metab Cardiovasc Dis 22 (2012) 167–175]. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 75.	2.6	0

#	Article	IF	CITATIONS
109	The quality of reporting in clinical research: the CONSORT and STROBE initiatives. Aging Clinical and Experimental Research, 2013, 25, 9-15.	2.9	31
110	Pulmonary Hypertension in CKD. American Journal of Kidney Diseases, 2013, 61, 612-622.	1.9	119
111	Effects of weight loss on renal function in obese CKD patients: a systematic review. Nephrology Dialysis Transplantation, 2013, 28, iv82-iv98.	0.7	167
112	An overview on standard statistical methods for assessing exposure-outcome link in survival analysis (Part II): the Kaplan-Meier analysis and the Cox regression method. Aging Clinical and Experimental Research, 2012, 24, 203-206.	2.9	29
113	Prognostic models in the clinical arena. Aging Clinical and Experimental Research, 2012, 24, 300-304.	2.9	4
114	Glitazones in chronic kidney disease: Potential and concerns. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 167-175.	2.6	18
115	Serum creatinine and the search for new biomarkers of acute kidney injury (AKI): the story continues. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1495-9.	2.3	8
116	An overview of standard statistical methods for assessing exposure-outcome link in survival analysis (Part I): basic concepts. Aging Clinical and Experimental Research, 2012, 24, 109-112.	2.9	4
117	Parathyroid Hormone and Mobilization of Circulating Bone Marrow-Derived Cells in Uremic Patients. Journal of Investigative Medicine, 2011, 59, 823-828.	1.6	12
118	NGAL is a Precocious Marker of Therapeutic Response. Current Pharmaceutical Design, 2011, 17, 844-849.	1.9	15
119	Levels of Neutrophil Gelatinase-Associated Lipocalin in 2 Patients With Crush Syndrome After a Mudslide. American Journal of Critical Care, 2011, 20, 405-409.	1.6	6
120	Obestatin: A New Element for Mineral Metabolism and Inflammation in Patients on Hemodialysis. Kidney and Blood Pressure Research, 2011, 34, 104-110.	2.0	11
121	Ultrafiltration intensification in hemodialysis patients improves hypertension but increases AV fistula complications and cardiovascular events Journal of Nephrology, 2011, 24, 465-473.	2.0	31
122	Vasopressin beyond water: implications for renal diseases. Current Opinion in Nephrology and Hypertension, 2010, 19, 499-504.	2.0	37
123	Neutrophil Gelatinase-Associated Lipocalin Levels in Patients With Crohn Disease Undergoing Treatment With Infliximab. Journal of Investigative Medicine, 2010, 58, 569-571.	1.6	38
124	Parathyroid Hormone Variability Parameters for Identifying High Turnover Osteodystrophy Disease in Hemodialysis Patients: An Observational Retrospective Cohort Study. Therapeutic Apheresis and Dialysis, 2010, 14, 566-571.	0.9	8
125	From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology. European Journal of Clinical Investigation, 2010, 40, 273-276.	3.4	86
126	Neutrophil gelatinaseâ€associated lipocalin levels in chronic haemodialysis patients. Nephrology, 2010, 15, 23-26.	1.6	28

#	Article	IF	CITATIONS
127	Alterations of Lipid Metabolism in Chronic Nephropathies: Mechanisms, Diagnosis and Treatment. Kidney and Blood Pressure Research, 2010, 33, 100-110.	2.0	32
128	Both IL- $1\hat{l}^2$ and TNF- $\hat{l}\pm$ Regulate NGAL Expression in Polymorphonuclear Granulocytes of Chronic Hemodialysis Patients. Mediators of Inflammation, 2010, 2010, 1-7.	3.0	12
129	Neutrophil gelatinase-associated lipocalin immunoexpression in renal tumors: Correlation with histotype and histological grade. Oncology Reports, 2010, 24, 305-10.	2.6	27
130	Neutrophil gelatinaseâ€associated lipocalin serum evaluation through normal pregnancy and in pregnancies complicated by preeclampsia. Acta Obstetricia Et Gynecologica Scandinavica, 2010, 89, 275-278.	2.8	47
131	Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: A new protein enters the scene. Cancer Letters, 2010, 288, 10-16.	7.2	150
132	Aquaretic inhibits renal cancer proliferation: Role of vasopressin receptor-2 (V2-R). Urologic Oncology: Seminars and Original Investigations, 2010, 28, 642-647.	1.6	19
133	Neutrophil gelatinase-associated lipocalin levels in patients with crohn disease undergoing treatment with infliximab. Journal of Investigative Medicine, 2010, 58, 569-71.	1.6	15
134	Neutrophil gelatinase-associated lipocalin (NGAL): a new piece of the anemia puzzle?. Medical Science Monitor, 2010, 16, RA131-5.	1.1	28
135	Neutrophil gelatinase-associated lipocalin in the intensive care unit: Time to look beyond a single, threshold-based measurement?. Critical Care Medicine, 2009, 37, 2864.	0.9	0
136	Increased Plasma Neutrophil Gelatinase-Associated Lipocalin Levels Predict Mortality in Elderly Patients with Chronic Heart Failure. Rejuvenation Research, 2009, 12, 7-14.	1.8	113
137	Arrhythmias and Hemodialysis: Role of Potassium and New Diagnostic Tools. Renal Failure, 2009, 31, 75-80.	2.1	13
138	Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Progression of Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 337-344.	4.5	447
139	Neutrophil gelatinase-associated lipocalin (NGAL) reflects iron status in haemodialysis patients. Nephrology Dialysis Transplantation, 2009, 24, 3398-3403.	0.7	41
140	NGAL: A New Missing Link between Inflammation and Uremic Anemia?. Renal Failure, 2009, 31, 622-623.	2.1	5
141	Erythropoietin and Cancer: An Old Risk. American Journal of Kidney Diseases, 2009, 53, 1102.	1.9	2
142	The erythropoietin and regenerative medicine: a lesson from fish. European Journal of Clinical Investigation, 2009, 39, 993-999.	3.4	12
143	Perioperative Iloprost and Endothelial Progenitor Cells in Uremic Patients With Severe Limb Ischemia Undergoing Peripheral Revascularization. Journal of Surgical Research, 2009, 157, e129-e135.	1.6	18
144	Malnutrition in the Elderly Patient on Dialysis. Renal Failure, 2009, 31, 239-245.	2.1	36

#	Article	IF	Citations
145	Neutrophil Gelatinase-Associated Lipocalin as an Early Biomarker of Nephropathy in Diabetic Patients. Kidney and Blood Pressure Research, 2009, 32, 91-98.	2.0	154
146	Neutrophil gelatinase-associated lipocalin in the intensive care unit: Time to look beyond a single, threshold-based measurement?. Critical Care Medicine, 2009, 37, 2864.	0.9	5
147	Renal Complications in Oncohematologic Patients. Journal of Investigative Medicine, 2009, 57, 892-901.	1.6	6
148	Regenerative Medicine: Does Erythropoietin have a Role?. Current Pharmaceutical Design, 2009, 15, 2026-2036.	1.9	17
149	Down with the Erythropoietin. Long Live the Erythropoietin!. Current Drug Targets, 2009, 10, 1028-1032.	2.1	12
150	Pregnancy in uremic patients: An eventful journey. Journal of Obstetrics and Gynaecology Research, 2008, 34, 137-143.	1.3	9
151	Aquareticâ€induced apoptosis: a cure or a curse?. European Journal of Clinical Investigation, 2008, 38, 874-875.	3.4	2
152	Neutrophil Gelatinase–Associated Lipocalin (NGAL) as a Marker of Kidney Damage. American Journal of Kidney Diseases, 2008, 52, 595-605.	1.9	472
153	Pathological and Prognostic Value of Urinary Neutrophil Gelatinase-Associated Lipocalin in Macroproteinuric Patients with Worsening Renal Function. Kidney and Blood Pressure Research, 2008, 31, 274-279.	2.0	70
154	Neutrophil Gelatinase-Associated Lipocalin Reflects the Severity of Renal Impairment in Subjects Affected by Chronic Kidney Disease. Kidney and Blood Pressure Research, 2008, 31, 255-258.	2.0	103
155	A Case-by-Case Protocol of Membranous Nephropathy Treatment with Endovenous Infusion of High Doses of Human Immunoglobulins. Nephron Clinical Practice, 2008, 108, c113-c120.	2.3	2
156	Dialysis and the Elderly: An Underestimated Problem. Kidney and Blood Pressure Research, 2008, 31, 330-336.	2.0	32
157	Effect of immunoglobulin treatment on endothelial progenitor cells in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2008, 67, 1047-1048.	0.9	5
158	Circulating Progenitor Cells after Cold Pressor Test in Hypertensive and Uremic Patients. Hypertension Research, 2008, 31, 717-724.	2.7	23
159	Effect of a Single Intravenous Immunoglobulin Infusion on Neutrophil Gelatinase-Associated Lipocalin Levels in Proteinuric Patients With Normal Renal Function. Journal of Investigative Medicine, 2008, 56, 997-1003.	1.6	29
160	Neurobiological model and quality of life in discovering personality of the uremic patient. Journal of Nephrology, 2008, 21 Suppl 13, \$139-45.	2.0	1
161	Preeclampsia and cardiovascular risk: general characteristics, counseling and follow-up. Journal of Nephrology, 2008, 21, 663-72.	2.0	3
162	Aquaretic Agents: Whats Beyond the Treatment of Hyponatremia?. Current Pharmaceutical Design, 2007, 13, 865-871.	1.9	23

#	Article	IF	CITATIONS
163	Erythropoietin and its lost receptor. Nephrology Dialysis Transplantation, 2007, 22, 1484-1485.	0.7	22
164	Effects of Haemodialysis on Circulating Endothelial Progenitor Cell Count. Blood Purification, 2007, 25, 242-251.	1.8	25
165	Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients. Nephrology Dialysis Transplantation, 2007, 23, 414-416.	0.7	119
166	Pulmonary Hypertension and Erythropoietin. Kidney and Blood Pressure Research, 2007, 30, 248-252.	2.0	28
167	Caffeine and the Kidney: What Evidence Right Now?. , 2007, 17, 225-234.		31
168	Neutrophil Gelatinase-Associated Lipocalin in Patients with Autosomal-Dominant Polycystic Kidney Disease. American Journal of Nephrology, 2007, 27, 373-378.	3.1	141
169	Aquaporin-2 (AQP2) Urinary Excretion and Assumption of Water with Different Mineral Content in Healthy Subjects. Renal Failure, 2007, 29, 567-572.	2.1	4
170	CIRCULATING ENDOTHELIAL PROGENITOR CELL MOBILIZATION IN CENTENARIANS: A POWERFUL SOURCE FOR EXTENDED RENAL LIFE. Journal of the American Geriatrics Society, 2007, 55, 1693-1694.	2.6	7
171	Experimental Therapies in Renal Replacement: The Effect of Two Different Potassium Acetate-free Biofiltration Protocols on Striated Muscle Fibers. Therapeutic Apheresis and Dialysis, 2007, 11, 375-381.	0.9	4
172	Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. , 2005, , CD003266.		52